News
In each issue, you’ll find stories about our faculty, staff, research initiatives, and events, as well as future updates from fellow alumni. It’s our way of staying connected with you and celebrating the ongoing accomplishments of our research community. Please reach out to us at [email protected] to share any achievements you'd like to include in a future edition.
We hope you enjoy this first edition and look forward to bringing you many more updates in the future.
ZQ Wang and Bob Geraghty
Co-Directors, Center for Drug Design
The Center for Drug Design (CDD) in collaboration with the University of Minnesota Technology Commercialization team, and our industry Licensee, TOPIX Pharmaceuticals, Inc., held a mini-symposium where attendees engaged in a scientific discussion on ProteXidine's journey from lab to market. ProteXidine is a proprietary biomimetic decoy molecule enhances skin's natural ability to mitigate damage caused by UV exposure and Reactive Oxygen Species (ROS). Ongoing scientific research continues to reveal promising new applications. ProteXidine®: The Intersection of Science, Technology, and Skin-Aging.
For 20 years, the University of Minnesota Center for Drug Design has combined research and scholarship to develop novel drugs for therapeutic applications, such as HIV, other human viral pathogens, neurological diseases, cancers, and much more. CDD research featuring numerous internal and external collaborations and shared within the broad scientific community is typically geared toward developing innovative and marketable technologies to benefit human health.
We celebrated the CDD's 20th Anniversary with a one-day symposium on Tuesday, May 7th, 2024 at McNamara Alumni Center in Minneapolis, MN. Symposium speakers included internationally renowned drug researchers Dr. Dennis Liotta, Dr. Pei-Yong Shi as invited keynote speakers and Dr. Bob Vince as the Founding Director of the CDD.
Researchers from the University of Minnesota Center for Drug Design are getting closer to finding a solution to the problem of White Nose Syndrome affecting bat populations throughout the country.
If there was a way to catch Alzheimer's earlier, to see its onset in the most nascent of stages, medical researchers postulate that would allow patients to access novel treatments earlier than ever before.
Finding a viable treatment for Alzheimer’s disease (AD) continues to frustrate researchers around the world.
The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning.
